Total Men's Primary Care - Kyle
Total Men's Primary Care - Kyle · 5401 Farm to Market 1626 · Kyle, TX 78640
4.9· 1,047 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
The Kyle, Texas, location of Total Men's Primary Care belongs to a chain whose website describes primary care redesigned around patients' time, including online check-in and a lobby with snacks and TVs rather than a dated waiting room. The site also lists men's health, low-T and erectile dysfunction care, and this location is listed for weight-loss care, hormone care and IV services. It holds a 4.9-star Google rating across 1,047 reviews that go back to 2019, 87 of them posted in the past year, and reviewers most often mention the staff, scheduling and the providers' knowledge.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-25. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.9 across 1,047 Google reviews. Of the 100 reviews we analyzed, 94 (94%) are positive (4–5★) and 5 (5%) are negative (1–2★).
What patients like
- Friendly, helpful staff43 reviews
- Knowledgeable, professional providers17 reviews
- Easy scheduling and communication15 reviews
- Feeling listened to5 reviews
Common complaints
- Staff or front-desk issues3 of 5 negative
- Scheduling or communication problems3 of 5 negative
- Billing, pricing or insurance problems2 of 5 negative
Most recent Google reviews
Kevin B.★★★★★2026-09-24The staff at Men’s Total Health was friendly and welcoming from the moment I walked in. Everyone, from the front desk staff to the nurse and doctor, was professional, helpful, and made me feel comfortable throughout my visit. Great experience overall!
Robert M.★★★★★2026-09-16Total Mens of Kyle has been a excellent clinic and the staff is so wonderful!!! Ive been coming here for 8 years and plan on going for more years to come!!!
Elliott t.★★★★★2026-09-10Great experience here in Kyle TX. First time patient, Very satisfied with the receptionist, nurse and doctor.
Tyler G.★★★★★2026-09-03Very helpful front desk
Mike N.★★★★★2026-09-02Quick friendly check-in and short wait to see PA. Details discussion of next steps.
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Nearby providers in Kyle
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs